Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C E Hack

Showing results (241-250 of 369) with videos related to

Pageof 37
Sort By:
Thrombosis and Haemostasis|January 1, 1996
Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulationS Sundaram, N Gikakis, C E Hack, et al.
British Journal of Haematology|October 1, 1992
Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemiaJ W Baars, J P de Boer, J Wagstaff, et al.
Thrombosis and Haemostasis|August 4, 1987
Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassaysJ H Nuijens, C C Huijbregts, M Cohen, et al.
Annals of the Rheumatic Diseases|June 17, 2005
Infliximab treatment reduces complement activation in patients with rheumatoid arthritisA Familian, A E Voskuyl, G J van Mierlo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2001
The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sitesB A Bladergroen, M C Strik, N Bovenschen, et al.
Clinical Immunology (Orlando, Fla.)|February 9, 2010
C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activationP M van der Zee, E Biró, L A Trouw, et al.
Cancer Treatment Reviews|June 1, 1989
A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2J Wagstaff, J B Vermorken, G Schwartsmann, et al.
Transplantation Proceedings|December 29, 1998
Selective expansion of a peripheral blood CD8+ memory T cell subset expressing both granzyme B and L-selectin during primary viral infection in renal allograft recipientsI J ten Berge, P C Wever, R J Rentenaar, et al.
The American Journal of Medicine|January 1, 1989
Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsisC E Hack, J H Nuijens, R J Felt-Bersma, et al.
Blood|March 15, 1996
Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastaseP M Jansen, R A Pixley, M Brouwer, et al.
Pageof 37

Showing results (241-250 of 369) with videos related to

Sort By:
Pageof 37
Thrombosis and Haemostasis|January 1, 1996
Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulationS Sundaram, N Gikakis, C E Hack, et al.
British Journal of Haematology|October 1, 1992
Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemiaJ W Baars, J P de Boer, J Wagstaff, et al.
Thrombosis and Haemostasis|August 4, 1987
Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassaysJ H Nuijens, C C Huijbregts, M Cohen, et al.
Annals of the Rheumatic Diseases|June 17, 2005
Infliximab treatment reduces complement activation in patients with rheumatoid arthritisA Familian, A E Voskuyl, G J van Mierlo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2001
The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sitesB A Bladergroen, M C Strik, N Bovenschen, et al.
Clinical Immunology (Orlando, Fla.)|February 9, 2010
C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activationP M van der Zee, E Biró, L A Trouw, et al.
Cancer Treatment Reviews|June 1, 1989
A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2J Wagstaff, J B Vermorken, G Schwartsmann, et al.
Transplantation Proceedings|December 29, 1998
Selective expansion of a peripheral blood CD8+ memory T cell subset expressing both granzyme B and L-selectin during primary viral infection in renal allograft recipientsI J ten Berge, P C Wever, R J Rentenaar, et al.
The American Journal of Medicine|January 1, 1989
Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsisC E Hack, J H Nuijens, R J Felt-Bersma, et al.
Blood|March 15, 1996
Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastaseP M Jansen, R A Pixley, M Brouwer, et al.
Pageof 37